A side-by-side comparison of tumor targeting and biodistribution of DARPins 9–29 and G3 demonstrated that DARPin G3 provides higher tumor uptake and tumor-to-organ ratios due to its smaller size and higher affinity in comparison to 9–29, which results in a preferable candidate for HER2 imaging [74]. The gene discussed is ERBB2; the disease is neoplasm.